Physician profile
William R Shoemaker
NPI 1891868352
$4,336.15
in general payments reported to CMS, 2019-2025
44 companies · $831 in 2025
The $831 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $182 · 2021: $518 · 2022: $516 · 2023: $718 · 2024: $1,025 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,573.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,305.61 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $371.11 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.65 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $233.27 | 2019-2024 | Rinvoq, Synthroid |
| Glaxosmithkline, LLC. | $201.60 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $194.41 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Pfizer INC. | $189.54 | 2019-2025 | |
| Lilly USA, LLC | $149.44 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.32 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $134.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $132.94 | 2022-2025 | Veozah |
| Esperion Therapeutics, INC. | $117.45 | 2020-2025 | Nexletol |
| Abbott Laboratories | $72.69 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $63.62 | 2022 | |
| Amarin Pharma, INC. | $63.44 | 2019-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Shoemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.